A widening gulf between the stock performances of Novo and its main competitor Lilly has drawn comparison with two of the world’s largest luxury-goods makers https://t.co/laJDl6f0bK ...

All right, let's uh look at Burke because the results just out. 213 a share included a 7-cent charge uh related to the closing of a a pharma license agreement. Revenue slipped 2% over the prior year.That's the chart I wanted to look at here. Uh it's been I mean at best like a bond uh with a 3.8% yield. Um now a 3.8% yield.that uh obviously when it was at $130 a share was not a uh as big of a yield. This is the problem. You have the one of the greatest drugs in history, but it doesn't last forever.Kruda and ...

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an e ...

Ardelyx (ARDX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on August 4, might help the stock move higher if these key numbers are better than expectations. O ...

Company Overview - Soleno Therapeutics, Inc. (SLNO) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3][12] - The company has a Zacks Rank of 2 (Buy), suggesting favorable market performance [4][12] Price Performance - SLNO shares have increased by 6.91% over the past week, while the Zacks Medical - Drugs industry has decreased by 0.38% during the same period [6] - Over the past quarter, SLNO shares have risen by 17.34%, and they have gained 87.5% over the last year, outperforming the S&P 500's increases of 16.43% and 18.63%, respectively [7] Trading Volume - The average 20-day trading volume for SLNO is 1,461,273 shares, which is a useful indicator of market interest and price movement [8] Earnings Outlook - In the past two months, three earnings estimates for SLNO have been revised upwards, while none have been revised downwards, leading to an increase in the consensus estimate from -$3.09 to -$2.33 [10] - For the next fiscal year, two estimates have moved upwards with no downward revisions, indicating positive sentiment regarding future earnings [10]

Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY) and Stevanato Group (STVN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positi ...

Stevanato Group (STVN) shares rallied 10% in the last trading session to close at $27.95. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.6% gain over the past four weeks.The sharp rise in Stevanato’s stock price likely reflects growing investor confidence in the company’s revenue outlook, particularly from its high-value solutions segment. Strong demand for high-value syringes, increased production capacit ...

Bristol-Myers’ CEO is stepping down from his role after six years at the company, a surprise move as the drugmaker races to find its next hit https://t.co/uH71V6qvon ...

Bristol-Myers’ CEO is stepping down from his role after six years at the company, a surprise move as the drugmaker races to find its next hit https://t.co/RzMYh7aX68 ...

Siga Technologies Inc. (SIGA) ended the recent trading session at $7.06, demonstrating a -1.4% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.07%. On the other hand, the Dow registered a loss of 0.7%, and the technology-centric Nasdaq increased by 0.18%. The stock of company has risen by 11.18% in the past month, leading the Medical sector's gain of 2.39% and the S&P 500's gain of 5.71%.The investment community will be paying close attention t ...